The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Utilizing biology to improve on R-CHOP in DLBCL: targeting ubiquitous markers & mutational analysis
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil , Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the role of molecular biology in improving the efficacy of R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL). Dr Collins explains that while there has been a lot of research in targeting ubiquitous targets such as CD79B, BTK, and CD19 in trials such as POLARIX (NCT03274492), PHOENIX (NCT01855750), and ZUMA-12 (NCT03761056) respectively, it is important to analyze the mutational landscape of these patients as it has an impact on treatment response. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Honoraria: Roche, Takeda, Gilead, Pfizer, MSD, Celleron, ADC Therapeutics, Incyte, Beigene. Research funding: BMS, MSD, Celleron, Amgen, BMS
